Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRIMARY ENDPOINT MET; MEDIAN TIME TO ONSET OF SYMPTOM RELIEF ACHIEVED IN1.28 HOURS, SIGNIFICANTLY FASTER VERSUS PLACEBO (P

PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTENTIAL OF DEUCRICTIBANT FOR ON-DEMAND TREATMENT OF HAE ATTACKS

TOPLINE DATA FOR RAPIDE-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT IMMEDIATE-RELEASE CAPSULE FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS, EXPECTED IN 4Q2025 ENROLLMENT IN CHAPTER-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT EXTENDED-RELEASE TABLET FOR PROPHYLAXIS OF HAE ATTACKS, IS PROGRESSING AS PLANNED; TOPLINE DATA ANTICIPATED IN 2H2026 INITIATED CREAATE, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT FOR THE PROPHYLACTIC AND ON-DEMAND TREATMENT OF AAE-C1INH ATTACKS DATA PRESENTED AT RECENT MEDICAL CONGRESSES, INCLUDING FINAL OUTCOMES FROM THE COMPLETED OPEN-LABEL EXTENSION PHASE OF THE PHASE 2 CHAPTER-1 STUDY, REINFORCE THE POTENTIAL OF DEUCRICTIBANT TO DIFFERENTIATE THROUGH ITS EFFICACY AND SAFETY PROFILE STRONG FINANCIAL POSITION WITH CASH AND CASH EQUIVALENTS OF 329 MILLION AS OF SEPTEMBER 30, 2025 ZUG, SWITZERLAND, NOV. 12, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE. WE REMAIN ON TRACK TO REPORT DATA FROM THE PIVOTAL PHASE 3 TRIAL, RAPIDE-3, IN THE FOURTH QUARTER OF 2025, SAID BERNDT MODIG, CHIEF EXECUTIVE OFFICER OF PHARVARIS.

PHARVARIS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ZUG, SWITZERLAND, NOV. 10, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), SUMMARIZED THE PRESENTATIONS FROM THE 2025 ANNUAL MEETING OF THE AMERICAN COLLEGE OF ALLERGY, ASTHMA, AND IMMUNOLOGY (ACAAI), INCLUDING DATA FROM TWO ORAL PRESENTATIONS AND SIX POSTERS, WHICH TOOK PLACE FROM NOVEMBER 6-10, 2025, IN ORLANDO, FLA.

DATA SUPPORTING THE POTENTIALLY DIFFERENTIATED PHARVARIS PORTFOLIO PRESENTED AT ACAAI 2025 ANNUAL SCIENTIFIC MEETING

ZUG, SWITZERLAND, OCT. 23, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ORAL BRADYKININ B2 RECEPTOR ANTAGONISTS TO HELP ADDRESS UNMET NEEDS OF THOSE LIVING WITH BRADYKININ-MEDIATED DISEASES SUCH AS HEREDITARY ANGIOEDEMA (HAE) AND ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE-C1INH), TODAY ANNOUNCED THE ACCEPTANCE OF TWO ABSTRACTS FOR ORAL PRESENTATION AND SIX FOR POSTER PRESENTATION AT THE AMERICAN COLLEGE OF ALLERGY, ASTHMA, AND IMMUNOLOGY (ACAAI) 2025 ANNUAL SCIENTIFIC MEETING TO BE HELD FROM NOVEMBER 6-10, IN ORLANDO, FLORIDA.

Pharvaris N.V.

PHVS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Pharvaris N.V.

PHVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PHVS